tislelizumab + lenvatinib + GMOX

This is a combination therapy consisting of three agents: - **Tislelizumab** is a humanized IgG4 monoclonal antibody that targets the programmed death-1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to enhance T-cell mediated immune responses against tumor cells. - **Lenvatinib** is an oral multikinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR 1–3), fibroblast growth factor receptors (FGFR 1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. It inhibits angiogenesis and tumor proliferation. - **GMOX** appears to refer to a veterinary formulation containing amoxicillin trihydrate and gentamicin sulfate as active ingredients[7]. Amoxicillin is a beta-lactam antibiotic inhibiting bacterial cell wall synthesis; gentamicin is an aminoglycoside antibiotic inhibiting protein synthesis in bacteria. The combination of tislelizumab and lenvatinib has demonstrated efficacy in advanced hepatocellular carcinoma (HCC) as both neoadjuvant therapy and in combination with transarterial chemoembolization (TACE)[2][3][8]. The addition of "GMOX" as described in available sources refers to an antimicrobial veterinary product, not typically used or studied in human oncology regimens. There are no clinical data supporting the use of this exact triple combination for any human disease.

Other names

tislelizumab plus lenvatinib plus GMOXtislelizumab + lenvatinib + GMOX